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INTRODUCTION 
 Chronic Kidney Disease is defined as ‘kidney damage with or without 
decreased GFR, manifested as either pathological abnormalities or presence of 
markers of kidney damage, including abnormalities in composition of blood or 
urine, abnormality renal imaging findings, for at least 3 months, or by a GFR 
below 60 ml/min/1.73 m2 body surface area’1. This broad definition includes 
patients with or without symptoms of kidney disease. 
CARDIOVASCULAR DISEASE IN CKD: 
CKD is a worldwide health problem. According to World Health 
Organization Global Burden of Disease project, CKD is the 12 th leading cause 
of death and 17th cause of disability2. The incidence of ESRD is increasing 
worldwide at an annual growth rate of 8%3.  
ESRD patients have extremely high morbidity and mortality from CVD. 
Based on data from the U.S. Renal Data System Coordinating Centre - Case 
Mix Adequacy Study, the prevalence of clinical coronary heart disease in 
hemodialysis patients is 40%, and CVD mortality is 10 to 30 times higher than 
in the general population despite stratification by gender, age, race, and the 
presence of diabetes4.   
The exact prevalence of CKD in India is not clear and the quality of that 
provided by small observational studies & personal experiences is quiet uneven. 
A small beginning has been made by the start of CKD registry in India 
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(www.ckdri.org). There are only three population based studies in India. In a 
prevention program started at community level in Chennai, the reported 
prevalence is 0.86% in the project population and 1.39% in the control region. 
The second study is based on Delhi involving 4972 urban patients. The 
prevalence of CKD (defined as serum creatinine more than 1.8 mg/dl) was 0.79 
% or 7852 per million/population. The third study, perhaps the only longitudinal 
study to identify the incidence of ESRD is based on 572,029 subjects residing in 
city of Bhopal suggests that the average crude and age adjusted incidence rates 
of ESRD were 151 and 232 per million population respectively5. “Screening 
and Early Evaluation of Kidney Disease” (SEEK) study was started in 2006 
in India which has reported a very high prevalence of 17.4% of CKD among 
5,623 participants; 7% out of these were in CKD Stage 1; 4.3% were in CKD 
Stage 2; 5% were in CKD Stage 3 and 1.6% in CKD Stage 4 and 5. 
  India is projected to become the major reservoir of chronic diseases like 
diabetes and hypertension. Since 25–40% of these subjects may develop CKD, 
the ESRD burden will rise. In absolute numbers the countries with the largest 
projected number of cases in 2030 will be India (79.4 million), China (42.3 
million) and the USA (30.3 million)6. 
Cardiovascular disease (CVD) is the leading cause of morbidity and 
mortality in patients at every stage of CKD. The incremental risk of CVD in 
those with CKD compared to the general population ranges from 10 to 200 fold, 
depending on the stage of CKD. 30-45% of patients reaching stage 5 CKD 
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already have advanced cardiovascular complications. As a result, most patients 
with CKD succumb to cardiovascular disease before ever reaching stage 5 
CKD. Thus, the focus of patient care in earlier CKD stages should be directed to 
the prevention of cardiovascular complications7.  
  The increased prevalence of vascular diseases in CKD patients derives 
from both traditional ("classic") and non-traditional (CKD-related) risk factors. 
Traditional risk factors include hypertension, hypervolemia, dyslipidemia, 
sympathetic over activity and hyperhomocysteinemia. Non Traditional Risk 
Factors are proteinuria, homocysteinemia, lipoprotein(a) and apolipoprotein(a) 
isoforms abnormality, anemia, abnormal calcium / phosphate metabolism, 
extracellular fluid overload,  oxidative stress, inflammation, malnutrition and 
thrombogenic factors. 
DYSLIPIDEMIA IN CKD: 
The most common dyslipidemia observed in patients with CKD is 
atherogenic dyslipidemia—a combination of hypertriglyceridemia and low 
levels of high-density lipoprotein cholesterol8. Dyslipidemia is believed to play 
a role in both the development of cardiovascular disease and the progression of 
renal disease regardless of the underlying cause (e.g., diabetes, hypertension) 
9,10. Increased levels of lipoprotein (a) are also common in CKD11.  
5 
 
Consequently, detecting & treating dyslipidemia in this population is as 
important as in populations without renal disorders, in order to prevent the 
development of CVD. 
The principal reason of this study is to find out the prevalence of 
dyslipidemia in CKD patients either on conservative therapy or dialysis, 
irrespective of aetiology except Diabetes Mellitus & Nephrotic syndrome (since 
they are independent risk factors for dyslipidemia) & to find out the type of 
hyperlipidemia in these patients and to compare it with the age & sex matched 
controls. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6 
 
AIMS AND OBJECTIVES 
 
 
a) To study the prevalence of dyslipidemia in chronic kidney disease, 
excluding diabetic and nephrotic aetiology and to compare it with the 
control population.    
b) To examine which type of hyperlipidemia predominates in these patients.   
c) To study whether any correlation exist between severity of CKD and lipid 
alteration. 
d) To study whether there is any difference in the pattern of dyslipidemia 
between CKD patients on conservative treatment and those on 
hemodialysis. 
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MATERIALS AND METHODS 
STUDY POPULATION:  
Hospital based 80 CKD patients in Chengalpattu Government Hospital 
(out-patient & in-patient) from September 1st, 2009 to November 30th, 2010.  
CONTROL POPULATION: 
 Age & sex matched 80 normal healthy controls are selected from the 
same hospital, who came with different illness other than the study disease. 
SELECTION CRITERIA FOR CASES:  
 
a. CKD patients on conservative therapy (at diagnosis) or dialysis (three 
months after initiating dialysis), irrespective of aetiology except 
nephrotic proteinuria and diabetes mellitus. 
b. Patients with serum creatinine ≥ 2 mg/dl AND bilateral contracted 
kidneys.  
• Patients are selected if they have bilateral contracted kidneys in 
ultrasonography of the abdomen i.e., if the kidneys in long axis are 
less than 9 cm and a serum creatinine ≥ 2 mg/dl. 
EXCLUSION CRITERIA FOR BOTH CASES AND CONTROLS: 
Exclude patients who are obese, with diabetes mellitus, those on beta -  
blockers & oral contraceptive pills, pregnant patients, patients with history of 
smoking and chronic alcohol intake. 
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Diabetes mellitus is ruled out by fasting and post-prandial blood sugar. 
Patients are excluded if they have FBS ≥ 100mg/dl & PPBS ≥140 mg/dl. 
Protein-to-creatinine ratio in early morning urine sample is used to exclude 
nephrotic proteinuria. Urine protein in mg and urine creatinine in mg is noted & 
their ratio is calculated. Cases were excluded if the ratio was >3.5 (correlates 
with 3.5 gm protein/24 hrs urine sample)12. There is a high degree of correlation 
between 24-hour urine protein excretion and protein-to-creatinine ratios in 
random, single-voided urine samples12. 
Obese patients are excluded since they have high VLDL & reduced HDL13. 
Obesity classification was based on Body Mass Index (BMI) which takes into 
account the weight and height of the patient. BMI = wt in kg / ht in m2. If BMI 
was ≥ 25 kg/m2, patients were excluded.  
Pregnant patients were excluded since VLDL is elevated in pregnancy13. 
Those on OCPs were excluded, since the oestrogen component increases 
HDL13. 
Beta blockers elevate VLDL & reduce HDL13, hence patients consuming it 
were excluded. 
A subject was classified as a non-smoker if he/she had smoked fewer than 
100 cigarettes in his/her lifetime and had stopped smoking at least 1 year back14. 
A non-drinker was classified as one who had never consumed alcoholic 
beverages14. Alcohol elevates HDL & VLDL, while smoking reduces HDL13, 
hence they were excluded. 
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 In the proforma, detailed history regarding the presenting symptoms like 
fatigue, weakness, pruritis, anorexia, nausea, vomiting, nocturia, polyuria, 
oliguria, insomnia, oedema, difficulty in breathing, etc., was enquired. Past 
history & history of dialysis was obtained. General examination including 
pallor, pulse rate, blood pressure, height & weight were noted & BMI 
calculated. Cardiovascular system, respiratory system, per abdomen 
examination & central nervous system examination including fundus 
examination was done.  
The following laboratory investigations were obtained – haemoglobin 
(g/dl), blood sugar – fasting & post prandial (mg/dl), blood urea (mg/dl), serum 
creatinine (mg/dl), electrolytes – sodium, potassium, chloride & bicarbonate 
(mEq/L). Creatinine clearance was calculated. Ultrasonography of the abdomen 
was done to measure the kidney size. Fasting lipid profile was done – Total 
Cholesterol (TC), Triglycerides (TG) and High Density Lipoproteins (HDL) 
were measured and Low Density Lipoproteins (LDL), Very Low Density 
Lipoproteins (VLDL) & TC/HDL ratio were calculated. Electrocardiogram, 
urine analysis & spot urine protein creatinine ratio were also done. All the data 
collected were analysed using SPSS (Statistical Package for the Social Science) 
system. 
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METHODOLOGY OF INVESTIGATIONS: 
 
TOTAL CHOLESTEROL: 
Method – Enzymatic one step method of Wybenga & Pileggi. 
Principle – Cholesterol reacts with hot solution of Ferric perchlorate, Ethyl 
acetate & sulphuric acid (cholesterol reagent) and gives a lavender coloured 
complex which is measured at 560 nm. 
 Cholesterol esters ---cholesterol esterase----> Cholesterol + Fatty acid 
 Cholesterol +O2        ------------------------------------ > Choleston-3-one + H2O2 
 2 H2O2 + Phenolic compound --------- > Quinonenine   
Sample – serum / plasma (after a 12 hr overnight fast). 
Reagents – Reagent 1: Cholesterol reagent 
             Reagent 2: Working cholesterol standard 200% 
          Reagent 3: Precipitating reagent  
Procedure: 
Mark 3 test tubes as Blank (B), Standard (S) & Test (T).  
 BLANK STANDARD TEST 
REAGENT 1 3 ml 3 ml 3 ml 
REAGENT 2 -  0.015 ml - 
SERUM / 
PLASMA 
- - 0.015 ml 
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Mix well & keep the 3 test tubes in a boiling water bath for 90 seconds. Cool 
them immediately to room temperature, under running tap water. Measure the 
Optic Density (OD) of B, S & T on a calorimeter with a yellow-green filter or 
on a spectrophotometer at 560 nm. 
Total cholesterol = (OD Test / OD Standard) x 200 
HIGH DENSITY LIPOPROTEIN: 
HDL is obtained in the supernatant after centrifugation using the same 
reagents mentioned above.  
Pipette 0.2 ml of the sample & 0.2 ml of the precipitating reagent, mix 
well, keep at R.T. for 10 min and then centrifuge at 2000 rpm for 15 min to 
obtain a clear supernatant. 
 BLANK STANDARD TEST 
REAGENT 1 3 ml 3 ml 3 ml 
REAGENT 2 -  0.015 ml - 
SUPERNATANT - - 0.12 ml 
Mix well & keep the tubes immediately in boiling water bath for 90 sec & cool 
them immediately to room temperature, under running tap water. Measure the 
Optic Density (OD) of B, S & T on a calorimeter with a yellow-green filter or 
on a spectrophotometer at 560 nm. 
HDL cholesterol = (OD Test / OD Standard) x 50 
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TRIGLYCERIDE:  
Method: Enzymatic – calorimetric method. 
Sample: Fasting samples of serum / EDTA or heparinised plasma.   
Principle:  
Triglycerides + H2O2  ----lipoprotein lipase --Æ Glycerol + Fatty acid 
Glycerol + ATP -------glycerol kinase, Mg2-----Æ Glycerol-3-phosphate + ADP 
Glycerol-3-phosphate + O2 ---GPO-------Æ Dihydroxyacetone Phosphate + H2O2 
2H2O2 + 4-aminoantipyrine + ADPS –peroxidiseÆRed Quinone 
GPO – Glycerol-3-phosphate Oxidase 
ADPS – N-ethyl-N-93-sulfopropyl)-m-anidisin 
The intensity of the purple coloured complex formed is directly 
proportional to the TG concentration in the sample measured at 546 nm. 
REAGENT 1 (Enzymes / Chromogen): Lipoprotein lipase, Glycerol kinase, 
Glycerol-3-phosphate oxidase, peroxidise, 4-aminoantipyrine & ATP. 
REAGENT 1A (Buffer): Pipes buffer, ADPS, Magnesium salt. 
STANDARD (TG 200 mg/dl): Glycerol. 
Method: Mix reagent 1 & 1A and bring it to R.T. 
 BLANK STANDARD TEST 
RECONSTITUTED 
REAGENT 
1 ml 1 ml 1 ml 
STANDARD -  10 ul - 
SAMPLE - - 10 ul 
Incubate for 5 min at 37o C. Mix and read at 546 nm. 
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VLDL-C is calculated using the formula, 
VLDL-C = triglycerides / 5 
LDL-C is estimated using the following equation: 
LDL-C = total cholesterol – (TG/5) – HDL-C 
The National Cholesterol Program (NCEP) Adult Treatment Panel 
(ATP) III guidelines indicate that the upper limit of normal for total cholesterol 
is 240 mg/dl, LDL- C is 130 mg/dl, TG is 200 mg/dl and the lower limit for 
HDL- C is 35 mg/dl. Hence study and control population with values crossing 
the above mentioned limits were considered to have dyslipidemia. 
  
BLOOD UREA: 
Urea was one of the first indicators used to measure GFR. Urea 
production is variable and is largely dependent on protein intake. With a 
molecular weight of 60 Daltons, urea is freely filtered at the glomerulus, but 
readily reabsorbed in the tubules, and the amount of tubular reabsorption is 
variable, because of which renal urea clearance usually underestimates the GFR. 
 Increased plasma urea levels are seen in decreased urine flow as 
occurring in patients with intravascular volume depletion, following diuretic 
intake15 and congestive heart failure. Increased urea due to increased production 
is seen with elevated dietary protein intake16, gastrointestinal bleeding, and 
tetracycline use.  
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On the other hand, reduced levels of plasma urea can be seen in patients 
with alcohol abuse and chronic liver disease17. 
Method: Mix 4 ml of buffer reagent with 1 ml of enzyme reagent. 
 STD SAMPLE 
SAMPLE - 10 ul 
STANDARD 10 ul - 
REAGENT 1000 ul 1000 ul 
Mix well & read after 30 secs initial absorbance of sample (A1s) and standard 
(A1std) and start timer simultaneously. Read again after 60 secs (A2s & A2std) 
at 340 nm. 
Calculation and linearity: 
UREA (mg/dl )=  (A2s –A1s) / (A2std – A1std) X 50 
SERUM CREATININE: 
Creatinine is small (molecular weight 113 Daltons), does not bind to 
plasma proteins, freely filtered by the renal glomerulus & also secreted by the 
renal tubule. Creatinine production is proportional to muscle mass. Age- and 
gender-associated differences are also largely attributable to differences in 
muscle mass.  
A number of methods are used to measure creatinine18,19. 
a) The original Folin-Wu method used the Jaffe’s reaction, which is being 
used with various modifications. The Jaffe’s reaction has also been adapted for 
use in auto analyzers. 
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METHOD: Creatinine reacts with alkaline picrate in the reagent & form 
reddish-orange complex, known as creatinine picrate which is measured 
calorimetrically. 
REAGENT: 0.75N NaOH, 0.04 N Picric acid, creatinine standards of various 
concentrations. 
PROCEDURE: Add 250 uL of picric acid with 250 uL of Sodium hydroxide in 
a test tube to which 50 uL of blood is added at room temperature. Reading is 
taken at 515 nm in the calorimeter.  
    b) The method of Hare, involved the isolation of creatinine by absorption on 
Lloyd's reagent20.  
    c) The direct alkaline picrate method of Bonsnes and Taussky18. 
    d) Other methods currently in use employ O-nitrobenzaldehyde (Sakaguchi 
reaction) and imidohydrolase19. 
 Glucose, fructose, pyruvate, acetoacetate, uric acid, ascorbic acid, 
cephalosporin and plasma proteins can all cause the Jaffe’s colorimetric assay to 
yield falsely high creatinine values21. Auto analyzer methods utilize the Jaffe’s 
reaction, but separate creatinine from non-creatinine chromogens by the rate of 
colour development22, thus avoiding most of the interference seen with the 
standard Jaffe’s method23. However, very high serum bilirubin levels can cause 
falsely low creatinine.  
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Serum creatinine is probably the most widely used indirect measure of 
GFR, its popularity being attributed to convenience and low cost. 
Unfortunately, it is very insensitive to even substantial decline in GFR. The 
GFR (measured by more accurate techniques described later) may be reduced 
by up to 50% before serum creatinine becomes elevated. 
GLOMERULAR FILTRATION RATE (GFR): 
GFR i s traditionally measured as the renal clearance of a particular 
substance or marker from plasma. The clearance of an indicator substance is the 
amount removed from plasma, divided by the average plasma concentration 
over the time of measurement, expressed in moles or weight of the indicator per 
volume per time. 
 Indeed, if we assume that there is no extra-renal elimination, tubular 
reabsorption or tubular secretion of the marker, then GFR can be calculated as 
follows:  
 
where U is the urine concentration, V is the urine volume, and P is the average 
plasma concentration of the marker over the time (T) of the urine collection.  
Characteristics of an ideal endogenous or exogenous marker for 
measuring GFR - constant production, safe, convenient, readily diffusible in 
extracellular space, no protein binding, freely filterable, no tubular reabsorption, 
no tubular secretion, no extra renal elimination or degradation, accurate & 
    Glomerular filtration rate = (U · V) / (P · T) 
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reproducible assay, no compound should interfere, inexpensive and no influence 
on the GFR. 
Estimated - GLOMERULAR FILTRATION RATE (e-GFR): 
 GFR can be calculated using the below formulae  
1) Cockcroft and Gault formula: 
e-GFR (ml/min)= [(140-age in yrs) x weight in kg] / (72 x s. creatinine) 
multiply by 0.85 if female24 
2) Equation from the Modification of Diet in Renal Disease study (MDRD): 
e-GFR (ml/min/1.73 m2) = 1.86 x (Plasma creatinine) – 1.154 x (age) – 0.203 
Multiply by 0.742 for women 
Multiply by 1.21 for African Americans 
Other formulae for e-GFR using serum creatinine and other clinical 
parameters: 
Formula Units Reference 
(100/Cr) - 12 if male ml/min/1.73 m2 Jelliffe25
(80/Cr) - 7 if female 
(Wt · (29.3 - 0.203 · Age)/(Cr · 14.4), if male ml/min Mawer26 
(Wt · (25.3 - 0.175 · Age)/(Cr · 14.4), if female 
(98 - 16 · (Age - 20)/20)/Cr, multiply by 0.90 if 
female 
ml/min/1.73 m2 Jelliffe25
((145 - Age)/Cr) - 3, multiply by 0.85 if female ml/min/70 kg Hull27
(27 - (0.173 · Age))/Cr, if male ml/min Bjornsson28
(27 - (0.175 · Age))/Cr, if female 
7.58/(Cr · 0.0884) - 0.103 · Age + 0.096 · Wt - 6.66, ml/min/1.73 m2  Walser29
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Formula Units Reference 
if male 
6.05/(Cr · 0.0884) - 0.080 · Age + 0.080 · Wt - 4.81, 
if female 
170 · Cr-0.999 · Age-0.176 · (0.762 if female) · (1.180 if 
black) · SUN-0.170 · Alb0.318 
ml/min/1.73 m2 Levey30 
 
 
Limitations of e-GFR (where creatinine clearance should be measured): 
a) Extremes of age 
b) Severe malnutrition / obesity 
c) Pregnant women 
d) Disorders of skeletal muscle 
e) Critically ill, paraplegia, quadriplegia & hospitalised patients since they lack 
stable renal function 
f) Prior to dosing drugs with severe toxicity & narrow therapeutic index. 
ULTRASOUND: 
  Sonographic images of the kidneys are generally obtained in the 
longitudinal and transverse planes. Overall renal echogenicity is generally 
compared with the liver on the right and the spleen on the left. The normal renal 
cortex is less echogenic than the liver and spleen. Underlying liver disease may 
alter this picture. The medullary pyramids are hypoechoic and their triangular 
shape points to the renal hilum. The renal cortex lies peripherally and the 
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separation from the medulla is usually demarcated by an echogenic focus due to 
the arcuate arteries along the corticomedullary junction.  
Renal size is easily measured sonographically. The normal longitudinal 
dimension of right kidney is 11 ± 1 cm and the left kidney is 11.5 ± 1 cm. The 
demonstration of increased echogenicity within the renal cortex may be useful 
in suggesting the presence of renal parenchymal (medical renal) disease31. The 
renal cortex may show increased echogenicity in patients with either acute or 
chronic kidney injury and this is generally related to interstitial fibrosis. The 
finding is bilateral. A patient with small, echogenic kidneys usually has ESRD. 
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REVIEW OF LITERATURE 
 
CHRONIC KIDNEY DISEASE: 
 
Criteria 
    Kidney damage for ≥3 months, with or without decreased GFR 
   •    Pathological abnormalities 
   
•    Markers of kidney damage  
   •    Urinary abnormalities (e.g., proteinuria) 
   •    Blood abnormalities  
   •    Imaging abnormalities 
 
   •    Kidney trasplantation 
 
GFR <60 ml/min/1.73 m2 for ≥3 months, with or without kidney damage 
  
STAGES OF CKD: 
  The recent Kidney Disease Outcomes Quality Initiative (K/DOQI 2002) 
guidelines have classified CKD into five stages32: 
Stage Description GFR (ml/min/1.73 m2) 
0 with risk factors for CKD >90 
1 kidney damagea with normal or ↑ GFR ≥90 
2 kidney damage with mild ↓ GFR 60–89 
3 moderate ↓ GFR 30–59 
4 severe ↓ GFR 15–29 
21 
 
Stage Description GFR (ml/min/1.73 m2) 
5 kidney failure <15 (or dialysis) 
 a - kidney damage includes persistent proteinuria, abnormal urine sediment, 
abnormal blood and urine chemistry or abnormal imaging. 
HISTORICAL ASPECTS: 
In 1773 urea was first isolated from human urine by Rouelle, and in 
1800 Fourcroy coined the term "urea". The term uremia was coined by 
Piorry & L’Heritier in 1840 which means ‘retention in blood of urea & other 
products of metabolism normally excreted in urine’.   
           Uremia is a complex condition with characteristic features resulting from 
renal failure, which causes accumulation of unexcreted waste products. Thus 
not all patients with renal failure are uraemic.                                                             
            In 1836, Richard Bright commented on the “milky serum” of patients 
with ESRD – almost certainly the first recognition of hyperlipidemia. 
In 1903, Strauss introduced blood urea as a diagnostic test for renal 
diseases33 and finally in 1931, Jolliffe and Smith introduced the concept of 
creatinine clearance for practical application. 
In 1926, Rehberg used exogenous creatinine to measure renal clearance 
as an estimate of GFR. In 1928, the concept of urea clearance as a measure of 
kidney function was described in detail by Moller, McIntosh, and Van Slyke. 
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Association between lipid abnormalities & renal disease was suggested 
by Virchow in 1860. Munk coined the term ‘Lipoid nephrosis’. 
RISK FACTORS: 
 
Non-modifiable risk factors: 
 
¾ Genetic factors 
¾ Racial factors - A large single-centre study in the UK of 771 patients with 
ESRD, showed a higher incidence of DN in patients from the Indian 
subcontinent, while hypertensive renal disease was more common in 
individuals of Caribbean and African descent (Pazianas et al. 1991). This 
was confirmed by a study in which Indo-Asians were shown to have higher 
susceptibility to DN (Buck and Feehally 1997). Furthermore, UK Asians 
with DN may have a faster rate of decline of GFR when compared to 
Caucasians. 
¾ Gender - ESRD is more common in males34. 
¾ Age - The K/DOQI review of 21 studies suggested that age was a risk factor 
for the progression of CKD34. One notable exception is type 1 DM where 
young age at diagnosis is associated with a faster rate of GFR decline. 
Modifiable risk factors: 
¾ Hypertension - has been shown to be both an initiation and progression 
factor for diabetic and other nephropathies. 
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¾ Proteinuria - the majority of studies showed an association between heavy 
proteinuria and a faster rate of GFR decline by univariate analysis. 
¾ Glycaemia - poor blood glucose control is a major factor in the initiation of 
nephropathy in susceptible diabetics, but evidence for a role in progression is 
conflicting. 
¾ Lipids - lipids may contribute to the initiation and progression of CKD as 
data from the Atherosclerosis Risk in Communities (ARIC) study in the 
United States has shown that hyperlipidemia (especially triglyceridaemia) is 
associated with an increased risk of ESRD35. 
¾ Others - hyperuricaemia, obesity, smoking, caffeine, alcohol and recreational 
drugs like heroin or opiates.  
The role of lipids in progressive kidney scarring - 
Glomerulosclerosis: Lipid hypothesis focused on the nephrotoxicity of lipids 
(Moorhead et al. 1982). Glomerular toxicity of lipids has included an increase 
in Pgc as well as functional and structural endothelial and mesangial changes. 
Glomerular endothelial and mesangial cells have receptors for both LDL and 
oxidized-LDL. LDL accumulates in the mesangial cells and matrix in 
dyslipidemic states (Schlondorff 1993). Under conditions of glomerular 
oxidative stress such as inflammation, deposited LDL undergoes oxidative 
modifications. This would, in turn, induce further inflammatory changes 
through the release of Monocyte Chemoattractant Protein-1 (MCP-1). This 
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would stimulate the influx of monocytes to the glomeruli and exacerbate 
glomerular injury. Such infiltration often precedes glomerulosclerosis. 
Reduction of hyperlipidemia by dietary or pharmacological means is protective 
in models of spontaneous and experimental glomerulosclerosis. 
CAUSE OF CHRONIC KIDNEY DISEASE AND END STAGE RENAL 
FAILURE: 
• Arteriopathic, i.e., renovascular disease, hypertensive disease 
• Diabetic ESRD 
• Glomerulonephritis 
• Infective / obstructive (chronic pyelonephritis, reflux nephropathy, 
benign prostatic hypertrophy, neurogenic bladder, renal stones disease) 
• Congenital / familial / hereditary (e.g. adult polycystic kidney disease, 
Alport's syndrome, cystinosis, oxalosis) 
• Toxic, e.g., drug induced such as analgesic nephropathy, other toxic 
agents 
• Neoplasms, e.g., kidney tumours 
• Systemic, e.g., myeloma, systemic lupus erythematosus, amyloidosis, 
henoch schonlein purpura, scleroderma, haemolytic uremic syndrome 
• Miscellaneous, e.g., Balkan nephropathy 
• Uncertain 
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PREVALENCE OF CKD: 
 Prevalence of CKD (GFR ≤ 60 ml/min/1.73 m2) according to National 
Health and Nutrition Examination Survey [NHANES] in US from 1999–
2000 with a study population of 4,101 was 3.8 %.  
 The last 2 decades have witnessed an epidemic growth in the number of 
subjects with type 2 diabetes, typically in association with obesity and 
increasing sedentary lifestyle36. Given the relatively slow natural history of 
diabetic glomerulosclerosis, it is possible that we are only beginning to see 
the impact of this increase in diabetes on the occurrence of kidney injury and 
that, this is shown as an increase in the prevalence of proteinuria and early 
stages of CKD as seen in NHANES 1999-2000 relative to the 1988-1994 
survey37. Thus, there is an ominous possibility that an increased prevalence 
of diabetes will considerably escalate future rates of CKD. 
EVALUATION OF CHRONIC KIDNEY DISEASE: 
Stage 
Evaluation Plan 
0  Screening CKD risk reduction 
1  Diagnose and treat cause, slow the progression, evaluate risk of 
cardiovascular disease 
2  Estimate progression 
3  Evaluate and treat complications 
4  Prepare for renal replacement therapy 
5  Initiate renal replacement therapy 
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CARDIOVASCULAR DISEASE AND CHRONIC KIDNEY DISEASE: 
Traditional Risk Factors like older  age, male gender, hypertension , 
high LDL, low HDL, diabetes, smoking, physical inactivity, menopause, family 
history of CVD & left ventricular hypertrophy and Non Traditional Risk 
Factors like proteinuria, homocysteinemia, lipoprotein(a) and apolipoprotein(a) 
isoforms abnormality, anemia, abnormal calcium / phosphate metabolism, 
extracellular fluid overload,  oxidative stress, inflammation (C-reactive protein), 
malnutrition, thrombogenic factors38 are similar for CKD & CVD. 
It is well established that patients with kidney failure are at high risk of 
cardiovascular mortality39,40. Patients with CKD experience a high rate of fatal 
and nonfatal CVD events prior to reaching ESRD41,42. Patients in all stages of 
CKD are therefore considered in the “highest risk group” for development of 
CVD and CKD is also recognized as a ‘cardiovascular risk equivalent’43-45. 
Cardiovascular mortality, defined by death due to arrhythmias, 
cardiomyopathy, cardiac arrest, myocardial infarction, atherosclerotic heart 
disease or pulmonary edema in the general population (NCHS multiple cause 
of mortality data files ICD 9 codes 402, 404, 410–414, and 425-429, 1993) 
was low when compared with CKD group46. 
The relationship between CKD and CVD is complex - CKD is a risk 
factor for CVD and CVD may be a risk factor for CKD. Several cardiovascular 
risk factors promote the development and progression of both CKD and CVD. 
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Declining kidney function, in turn, is associated with elevated levels of 
cardiovascular risk factors47. 
CARDIOVASCULAR DISEASE RISK FACTORS AS RISK FACTORS 
FOR CKD: 
1) Hypertension 
2) Diabetes - In the United Kingdom Prospective Diabetes Study 
(UKPDS), 10 years after diagnosis of diabetes, the prevalence of 
microalbuminuria was 25%, macroalbuminuria 5.3% and elevated plasma 
creatinine or kidney failure was 0.8%48. In the Framingham Heart Study 
offspring cohort, baseline dysglycemia was associated with future risk of 
developing CKD49. Among patients with diabetes, there appears to be a 
strong relationship between poor metabolic control and the risk for 
development of diabetic kidney disease. 
3) Smoking - In cross-sectional analysis of a population sample of 28,409 
individuals who were smokers (both former and current smoking), it was 
found that smoking was associated with an approximately 3 fold increased 
risk of proteinuria50. In a prospective study of patients with CKD, smoking 
cessation was associated with decreased rate of progression and 
postponement of kidney failure over a 2-year follow-up51. 
4) Dyslipidemia - In the Atherosclerosis Risk In Communities (ARIC) 
Study, high TG and low HDL-C were associated with an increased risk of 
28 
 
developing decreased kidney function. The Cholesterol and Recurrent 
Events (CARE) Study - a randomized double-blind placebo controlled trial 
of Pravastatin versus placebo in participants with previous MI and total 
plasma cholesterol <240 mg/dl, showed that Pravastatin appeared to slow the 
rate of loss of kidney function52. 
5) Metabolic syndrome 
LIPOPROTEIN METABOLISM: 
Lipoproteins are large macromolecular complexes that transport 
hydrophobic lipids (triglycerides [TG], cholesterol, and fat-soluble vitamins) 
through body fluids (plasma, interstitial fluid, and lymph) to and from tissues. 
They play an essential role in the absorption of dietary cholesterol, long chain 
fatty acids, and fat-soluble vitamins; the transport of TG, cholesterol and fat-
soluble vitamins from the liver to peripheral tissues; and the transport of 
cholesterol from peripheral tissues to the liver.  
Lipoproteins contain a core of hydrophobic lipids (TG and CE) surrounded 
by hydrophilic lipids (phospholipids, unesterified cholesterol) and proteins that 
interact with body fluids.  
The plasma lipoproteins are divided into 5 major classes based on their 
relative density: chylomicrons, very low density lipoproteins (VLDLs), 
intermediate-density lipoproteins (IDLs), low-density lipoproteins (LDLs), and 
high-density lipoproteins (HDLs). Most of the plasma TG is transported in 
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chylomicrons or VLDLs and most plasma cholesterol is carried as CE in LDLs 
and HDLs. 
The proteins associated with lipoproteins, called apolipoproteins, are 
required for the assembly, structure and function of lipoproteins. They activate 
enzymes important in lipoprotein metabolism and act as ligands for cell surface 
receptors. ApoA-I, which is synthesized in the liver and intestine, is found on 
virtually all HDL particles. ApoA-II is the second most abundant HDL 
apolipoprotein and is on approximately two-thirds of all HDL particles. ApoB is 
the major structural protein of chylomicrons, VLDLs, IDLs, and LDLs; one 
molecule of apoB, either apoB-48 (chylomicron) or apoB-100 (VLDL, IDL or 
LDL), is present on each lipoprotein particle. The human liver synthesizes 
apoB-100, and the intestine makes apoB-48 by mRNA editing. ApoE is present 
in multiple copies on chylomicrons, VLDL, and IDL, and it plays a critical role 
in the metabolism and clearance of TG-rich particles. ApoC-I, ApoC-II and 
ApoC-III also participate in the metabolism of TG-rich lipoproteins.  
THE EXOGENOUS AND ENDOGENOUS LIPOPROTEIN 
METABOLIC PATHWAYS: 
Transport of Dietary Lipids (Exogenous Pathway): 
Dietary TGs are hydrolyzed by lipases within the intestinal lumen and 
emulsified with bile acids to form micelles. Dietary cholesterol, fatty acids, and 
fat-soluble vitamins are absorbed in the proximal small intestine. Cholesterol 
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and retinol are esterified in the enterocyte to form CE and retinyl esters, 
respectively. Longer-chain fatty acids (>12 carbons) are incorporated into TG 
and packaged with apoB-48, CE, retinyl esters, phospholipids and cholesterol to 
form chylomicrons. Nascent chylomicrons are secreted into the intestinal lymph 
and delivered via the thoracic duct directly to the systemic circulation. The 
particles encounter LPL, which is anchored to proteoglycans in the capillary 
endothelial surfaces of adipose tissue, heart and skeletal muscle. The TGs of 
chylomicrons are hydrolyzed by LPL and FFAs are released. ApoC-II, which is 
transferred to circulating chylomicrons from HDL, acts as a cofactor for LPL in 
this reaction. The released FFA is taken up by adjacent myocytes or adipocytes 
and either oxidized to generate energy or reesterified and stored as TG. The 
chylomicron particle progressively shrinks in size as the hydrophobic core is 
hydrolyzed and the hydrophilic lipids and apolipoproteins on the particle 
surface are transferred to HDL, creating chylomicron remnants, which are 
rapidly removed from the circulation by the liver through a process that requires 
apoE as a ligand. Consequently, few, if any, chylomicrons or its remnants are 
present in the blood after a 12-h fast, except in patients with disorders of 
chylomicron metabolism. 
Transport of Hepatic Lipids (Endogenous Pathway): 
It refers to the hepatic secretion of apoB-containing lipoproteins and their 
metabolism. VLDL particles resemble chylomicrons, in protein composition but 
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contain apoB-100 rather than apoB-48 and have a higher ratio of cholesterol to 
TG (~1 mg of cholesterol for every 5 mg of TG). The TGs of VLDL are derived 
predominantly from the esterification of long-chain FA in the liver. The 
packaging of hepatic TG with the other major components of the nascent VLDL 
particle (apoB-100, CE, phospholipids, and vitamin E) requires the action of the 
enzyme microsomal TG transfer protein (MTP). After secretion into the plasma, 
VLDL acquires multiple copies of apoE and apolipoproteins of the C series by 
transfer from HDL. The TGs of VLDL are hydrolyzed by LPL, especially in 
muscle and adipose tissue. Now they are referred to as IDLs, which contain 
roughly similar amounts of cholesterol and TG. The liver removes 
approximately 40–60% of IDL by LDL receptor–mediated endocytosis via 
binding to apoE. The remainder of IDL is remodelled by hepatic lipase (HL) to 
form LDL. During this process, most of the TG in the particle is hydrolyzed and 
all apolipoproteins except apoB-100 are transferred to other lipoproteins. 
Approximately 70% of circulating LDL is cleared by LDL receptor–mediated 
endocytosis in the liver. Lp(a) is similar to LDL in lipid and protein 
composition, but it contains an additional protein called Apo(a). Apo(a) is 
synthesized in the liver and attached to apoB-100 by a disulfide linkage. The 
major site of clearance of Lp(a) is the liver. 
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THE EXOGENOUS AND ENDOGENOUS LIPOPROTEIN 
METABOLIC PATHWAYS 
 
HDL METABOLISM AND REVERSE CHOLESTEROL TRANSPORT: 
All nucleated cells synthesize cholesterol, but only hepatocytes and 
enterocytes can effectively excrete cholesterol from the body. In the liver, 
cholesterol is excreted into the bile, either directly or after conversion to bile 
acids. Cholesterol in peripheral cells is transported to the liver and intestine by a 
process termed "reverse cholesterol transport" that is facilitated by HDL. 
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Nascent HDL particles are synthesized by the intestine and the liver. 
Newly secreted apoA-I rapidly acquires phospholipids and unesterified 
cholesterol from intestine or liver, via efflux promoted by the membrane protein 
ATP-binding cassette protein A1 (ABCA1). This process results in the 
formation of discoidal HDL particles, which then recruit additional unesterified 
cholesterol from the periphery. Within the HDL particle, the cholesterol is 
esterified by LCAT, and the more hydrophobic CE moves to the core of the 
HDL particle. As HDL acquires more CE it becomes spherical, and additional 
apolipoproteins and lipids are transferred to the particles from the surfaces of 
chylomicrons and VLDLs during lipolysis. HDL CE can be transferred to apoB-
containing lipoproteins in exchange for TG by the CE transfer protein (CETP). 
The CE is then removed from the circulation by LDL receptor–mediated 
endocytosis & also be taken up directly by hepatocytes via the scavenger 
receptor class BI (SR-BI). 
HDL particles undergo extensive remodelling within the plasma by a 
variety of lipid transfer proteins and lipases. The phospholipid transfer protein 
has the net effect of transferring phospholipids from other lipoproteins to HDL. 
After CETP-mediated lipid exchange, the TG-enriched HDL becomes a much 
better substrate for HL, which hydrolyzes the TGs and phospholipids to 
generate smaller HDL particles. Endothelial lipase hydrolyzes HDL 
phospholipids, generating smaller HDL particles that are catabolised faster. 
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HDL METABOLISM AND REVERSE CHOLESTEROL TRANSPORT 
 
FRIEDRICKSON CLASSIFICATION OF HYPERLIPOPROTEINEMIA: 
TYPE  OVERNIGHT 
SERUM 
ELEVATED 
PARTICLES 
ASSOCIATED CLINICAL DISORDERS  SERUM 
TC
SERUM 
TG
I  Creamy top 
layer 
Chylomicrons  Lipoprotein lipase deficiency, 
apolipoprotein C‐II deficiency 
 
+ to ++  ++++ 
IIa  Clear  LDL  Familial hypercholesterolemia, 
polygenic hypercholesterolemia, 
nephrosis, hypothyroidism, familial 
combined hyperlipidemia 
 
++++  ‐‐ 
IIb  Clear  LDL,VLDL  Familial combined hyperlipidemia 
 
+++ ++
III  Turbid  Chylomicrons & 
VLDL remnants 
Dysbetalipoproteinemia
 
+++ +++
IV  Turbid  VLDL  Familial hypertriglyceridemia, familial 
combined hyperlipidemia, sporadic 
hypertriglyceridemia 
N+  ++ 
V  Creamy top, 
turbid 
bottom 
Chylomicrons & 
VLDL 
Diabetes +++ ++++
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SECONDARY DYSLIPIDEMIAS: 
• LDL-C is elevated in hypothyroidism, nephrotic syndrome, cholestasis, 
acute intermittent porphyria, anorexia nervosa, hepatoma and drugs like 
thiazide & cyclosporine. 
• HDL-C is decreased in smoking, type 2 DM, obesity, malnutrition, 
anabolic steroids and beta-blockers.  
• Elevated VLDL-C is seen in obesity, type 2 DM, glycogen storage 
disease, hepatitis, alcohol, renal failure, sepsis, stress, cushing's 
syndrome, pregnancy, acromegaly, lipodystrophy and drugs like  
estrogen, beta blockers, glucocorticoids, bile acid binding resins & 
retinoic acid.   
• Lipoproteins are elevated in renal insufficiency, menopause, 
hypothyroidism, acromegaly and drugs like growth hormone & 
isotretinoin. 
DYSLIPIDEMIA IN CKD:  
The most common dyslipidemia observed in patients with CKD is 
atherogenic dyslipidemia—a combination of hypertriglyceridemia, low levels of 
HDL-C and high levels of LDL particles53 & Lp(a)54. CKD patients have a 
different lipid profile with increased atherogenic lipid fractions, and hence 
serum LDL-C levels may underestimate the atherogenic effect of in these 
patients. As GFR falls, TG levels increase and HDL-C falls. As proteinuria 
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increases, total cholesterol, LDL-C and TG all increases, whereas HDL-C 
decreases. Approximately 50% of HD patients and 70% of PD patients 
demonstrate dyslipidemia55. HD patients characteristically demonstrate 
alterations only in TG (elevated) and HDL-C (reduced) levels. In PD and 
transplant patients, total cholesterol, LDL-C and TG are usually higher than in 
the general population. 
MECHANISM OF LIPID ABNORMALITIES IN CKD: 
  Alterations in low-density lipoprotein and cholesterol metabolism 
   
 Increased LDL generation  
    Increased apo B synthesis
    Increased CETP activity 
 
   
 Increased cholesterol synthesis  
    Increased HMG-CoA reductase activity
    Decreased cholesterol 7α-hydroxylase 
    Up-regulation of hepatic ACAT 
 
   
 Defects in LDL clearance  
    Reduction in hepatic LDL expression
    Reductions in apo B catabolism
 
 
 
 
   
 Alterations in very low density lipoprotein metabolism  
   
 Impaired VLDL clearance  
    Reduced LPL and hepatic lipase activity
    Reduced VLDL receptor 
    Impaired enrichment with apo E and apo C
 
   
 Increased hepatic production of fatty acids and triglycerides  
    Elevated enzymatic activity of acyl-CoA carboxylase and 
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fatty acid synthase 
    Increased hepatic DGAT activity
 
 
 
   
 Alterations in high-density lipoprotein  
    Diminished LCAT activity 
    Apo A-I enrichment of HDL 
    Reduced expression of HDL (SR-B1) receptor
 
 
           Increased Lp(a) synthesis
 
Though the above mechanisms are more common in nephrotic syndrome 
they are also proposed to play a role in CKD.  
Urinary losses of albumin and LPL activators result in an increase in LDL, 
which in turn bind to the glomerular basement membrane further impairing its 
permselectivity; filtered lipoproteins accumulate in the mesangium, stimulating 
extracellular matrix synthesis and mesangial cell proliferation; filtered LDL is 
taken up and metabolized by the tubules, leading to cell injury and interstitial 
disease. There is also defective clearance of TG from the body.  
ALTERATIONS IN LDL-C AND CHOLESTEROL METABOLISM:  
 
Increase in LDL and total cholesterol is attributable to both increased 
synthesis and impaired catabolism. There is an increased absolute synthesis rate 
of apoB-100, the principal apoprotein constituent of LDL. Significant 
reductions in apoB catabolism have also been demonstrated56. Plasma levels and 
the activity of CETP which mediates the transfer of esterified cholesterol from 
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HDL to VLDL remnants to yield LDL are enhanced.  There is also a reduced 
receptor-mediated LDL clearance57.  
A vicious cycle has been suggested in uremia in which the decreased 
catabolism of IDL and LDL leads to their increased plasma residence time and 
further modification of the apoB contained in these lipoproteins by oxidation, 
carbamylation and glycation58. These modifications lead to the reduced 
recognition and binding of these lipoproteins to LDL receptors and LRP in the 
liver and hence further reduction in plasma clearance by this physiologic 
pathway. 
HYPERTRIGLYCERIDEMIA: 
             Plasma TGs start to increase in early stages of CKD and show the 
highest concentrations in nephrotic syndrome and in dialysis patients, especially 
those who are treated with PD. The accumulation of TG is the consequence of 
both a high production rate and a low fractional catabolic rate59. An increased 
production of TG rich lipoprotein is possibly a consequence of impaired 
carbohydrate tolerance and enhanced hepatic VLDL synthesis60. The reduced 
fractional catabolic rate is likely due to the decreased activity of LPL and 
hepatic lipase, which can be attributed to the depletion of enzyme pool induced 
by frequent heparinization in HD patients61, an increase in the plasma apoC-
III/apoC-II ratio, and the presence of other lipase inhibitors in plasma. ApoC-II 
is an activator of LPL, whereas apoC-III is an inhibitor of LPL. The increased 
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apoC-III/apoC-II ratio is usually due to a disproportionate increase in plasma 
apoC-III. There is also a decrease in LPL synthesis as a result of secondary 
hyperparathyroidism or suppressed insulin level.  
ALTERATIONS IN HIGH-DENSITY LIPOPROTEIN:  
Diminished activity of the LCAT & apoA1 appears to contribute to the 
HDL-C abnormality62. LCAT is involved in catalyzing the esterification of 
cholesterol as well as the conversion of HDL3 to HDL2. Low LCAT levels 
would impair this HDL maturation, in turn reducing the transfer of apoC-II to 
VLDL and thus inhibiting the catabolism of TG-rich lipoproteins. Increased 
hepatic production and elevated plasma CETP levels may contribute to HDL 
abnormalities63. Elevated CETP levels might contribute to cholesterol 
enrichment of TG-rich lipoproteins, as well as the observed reductions in 
HDL264. There is a marked up-regulation of hepatic acetyl coenzyme A: 
cholesterol acyltransferase (ACAT) contributing to CKD induced dysregulation 
of HDL metabolism.  
Another important component of HDL is paraoxonase, an enzyme that 
inhibits the oxidation of LDL. Plasma paraoxonase activity is reduced in 
patients with CKD65, thereby predisposing the LDL and possibly also HDL 
particles to oxidation. Furthermore, infection associated or uremia associated 
inflammation might convert HDL from an antioxidant into a pro-oxidant 
particle66. All of these may contribute to atherogenesis in CKD. 
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ALTERATIONS IN VLDL-C METABOLISM:  
Defective receptor-mediated clearance of VLDL owing to hepatic lipase 
deficiency may underlie the elevated remnant particles in nephrotic syndrome67.  
APOLIPOPROTEIN A – IV (ApoA-IV): 
  ApoA-IV is a 46-kDa glycoprotein that is synthesized primarily in 
enterocytes of the small intestine.  It protects against atherosclerosis by 
promoting reverse cholesterol transport pathway. Specifically, apoA-IV 
activates LCAT and modulates the activation of LPL68 as well as the protein-
mediated transfer of CE from HDL to LDL. Cross-sectional studies have shown 
an inverse relationship between plasma apoA-IV levels and presence of CAD in 
the general population as well as in patients with CKD69.  
ApoA-IV has also been identified as a marker of primary CKD, and its 
plasma levels are already increased when GFR is still normal. Furthermore, high 
plasma apoA-IV concentrations predicts the progression of primary non-
diabetic kidney disease, during a prospective 7-yr follow-up study. A tubular 
type of proteinuria and severe proteinuria cause a decrease in plasma apoA-IV 
levels70. In dialysis patients, apoA-IV levels are twice as high as in the general 
population71.  
LIPOPROTEIN(a): 
 
Plasma Lp(a) levels are influenced by GFR. In patients with large apo(a) 
isoforms but not those with small apo(a) isoforms, plasma Lp(a) level begins to 
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increase in stage 1 CKD before GFR starts to decrease72. This isoform-specific 
increase in plasma Lp(a) levels was observed in several but not all studies in 
non-nephrotic patients with CKD and HD patients. In contrast, in patients with 
nephrotic syndrome73 and PD patients, increases in plasma Lp(a) levels occur in 
all apo(a) isoform groups, probably as a consequence of the pronounced protein 
loss and a subsequently increased production in the liver. After successful 
kidney transplantation, a decrease in plasma Lp(a) can be regularly observed in 
HD patients with large apo(a) isoforms and in PD patients with all apo(a) 
isoform groups. Thus, the elevation of Lp(a) in CKD is an acquired abnormality, 
mostly influenced by the degree of proteinuria and less by the cause of kidney 
disease. Malnutrition and inflammation have also been associated with high 
plasma Lp(a) levels in HD patients.   
PREVENTION ASPECT:  
The National Cholesterol Program (NCEP) Adult Treatment Panel 
(ATP) III guidelines indicate that the upper limit of normal for total cholesterol 
is 240 mg/dl, LDL- C is 130 mg/dl, TG is 200 mg/dl and the lower limit for 
HDL- C is 35 mg/dl. 
Therapeutic lifestyle changes (TLC) for dyslipidemia includes smoking 
cessation, diet, aerobic exercise and weight loss. The goal of the Step I NCEP 
diet is to reduce total cholesterol to less than 300 mg/day and in the Step II diet 
to less than 200 mg/day. Pharmacological management includes74 
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• HMG-CoA synthetase inhibitors 
• Fibric acid derivatives for hypertriglyceridemia 
 Use with caution 
 Gemfibrozil preferred 
• Niacin 
• Cholesterol absorption inhibitor 
 Ezetimibe — statin-sparing 
 No controlled trials in CKD 
(HMG-CoA synthetase inhibitors and fibric acid derivatives are associated with 
an enhanced risk of rhabdomyolysis, a risk factor for ATN). 
Recent data have suggested that statins have effects beyond lipid 
reduction and may have a beneficial anti-inflammatory and anti-fibrogenic 
effects75,76, which are commonly associated with many forms of progressive 
renal injury such as reduction in TGF- production and inhibition of the 
proliferative actions of platelet-derived growth factor77. 
The NCEP ATP III and K/DOQI guidelines recommend the below 
goals for treating dyslipidemia in CKD patients: 
Parameter NCEP ATP III goal K/DOQI Revision goal 
LDL-C (mg/dl) < 130 <100 
HDL-C (mg/DL) >40 >40 
TG (mg/dl) <150 <150 
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In the CARE (Cholesterol and Recurrent Events) study, over 4,000 
patients, with a subgroup of 1,700 patients with creatinine clearance <75 
ml/min, with previous MI and plasma total cholesterol <240 mg/dl were 
randomized to pravastatin 40 mg/day or placebo and followed for approximately 
5 years. These patients had a 28% (95% CI 0.55 to 0.95; p = 0.02) relative risk 
reduction and a 4% ARR in the primary end point (death from coronary disease 
or symptomatic nonfatal MI) when treated with pravastatin 40 mg/day78. 
PROTOCOL FOR TREATMENT OF DYSLIPIDEMIA 
 
DYSLIPIDEMIA MANAGEMENT: 
Dyslipidemia Goal Initiate Increase Alternative 
TG≥500 
mg/dl 
TG<500 
mg/dl 
TLC TLC + Fibrate 
or niacin 
Fibrate or 
Niacin 
LDL 100-129 
mg/dl 
LDL<100 
mg/dl 
TLC TLC + low 
dose Statin 
Bile acid seq 
or Niacin 
LDL≥130 LDL<100 TLC + low TLC + max Bile acid seq 
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 [TLC – Therapeutic Lifestyle Changes] 
The prospective randomized clinical trial - PREVEND IT (Prevention of 
Renal and Vascular End Stage Disease Intervention Trial)79 with 864 
patients with microalbuminuria were randomized to fosinopril 20 mg/day or 
matching placebo and to pravastatin 40 mg/day or matching placebo. 
Participants were followed for 4 years. Pravastatin 40 mg/day resulted in a non-
significant 13% reduction (0.87 [95% CI 0.49 to 1.57]; p = 0.649) in the primary 
end point of cardiovascular mortality and hospitalization for cardiovascular 
morbidity.  
In the VA-HIT (Veterans' Affairs High-Density Lipoprotein 
Intervention Trial), over 2,500 men with CHD were enrolled and randomized 
to gemfibrozil 1,200 mg/day or placebo. In this study, a subgroup of 1,000 men 
with a creatinine clearance <75 ml/min was identified. In post hoc analysis, 
these patients with mild to moderate CKD were found to have a 27% relative 
risk reduction (0.73 [95% CI 0.56 to 0.96]; p = 0.02) and a 6.3% absolute risk 
reduction in fatal and nonfatal MI80.   
Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm 
mg/dl mg/dl dose Statin dose Statin or Niacin 
TG≥200 
mg/dl & non-
HDL≥130 
mg/dl 
Non-HDL 
<130mg/dl 
TLC + low 
dose Statin 
TLC + max 
dose Statin 
Fibrate or 
Niacin 
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(ASCOT-LLA) showed a lower rate of the primary end point of nonfatal MI 
and fatal CHD in those patients with relatively mild renal dysfunction81. 
UK Heart and Renal Protection study (UK-HARP-I) used simvastatin 
20 mg/d which lowered LDL cholesterol by 26% in CKD patients. 
 The Study of Heart and Renal Protection (SHARP) is a large-scale, 
randomized, placebo-controlled trial designed to evaluate the effects of 
cholesterol-lowering treatment with simvastatin (20 mg/day) plus ezetimibe (10 
mg/day) on major cardiovascular events in patients with CKD without known 
CVD. This study had 9000 patients: 6000 with CKD (serum creatinine >1.5 
mg/dl in women and 1.7 mg/dl in men) and 3000 on dialysis. The primary 
outcome was the time to a first cardiovascular event to occur, defined as a 
composite of MI, cardiac death, stroke, or coronary or non-coronary 
revascularization. Progression of renal disease was a secondary outcome of the 
study. 
According to ATP III, 79.8% of a cross-sectional group of ESRD pts in 
the Dialysis Morbidity and Mortality Study (DMMS)82 had dyslipidemia. 
In a study conducted by B Shah, S Nair, et al., in Nephrology Section, 
PD Hinduja National Hospital's Research Centre, Mahim, Bombay83, it was 
observed that  
• CKD patients on conservative treatment had TG significantly elevated 
(mean=222.78 mg/dl) when compared to the other groups (HD, post-
transplant & control).  
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• The most common lipid abnormality observed in renal transplant 
patients is hypercholesterolemia (37.5%). The mean total cholesterol in 
post transplant was 217 mg/dl, followed by the group on conservative 
treatment (mean=211.33 mg/dl). Those on HD had mean total cholesterol 
(163.37 mg/dl) which was less than that of the normal controls (184.11 
mg/dl). But the differences in the total cholesterol between these groups 
were not statistically significant.  
• A decrease in HDL-C or increase in LDL-C was not noticed in the CKD 
group when compared with the controls. 
• A lower Apo A1/Apo B ratio was present in CKD patients on HD 
(p<0.001) and in those on conservative management (p<0.01). 
According to a study conducted by A. Madhusudhana Rao, et al., on 
lipid abnormalities, lipoprotein (a) and apoprotein pattern in non-
dialyzed patients with CKD84, among the various parameters tested, TGs 
were high in CKD stage 1-4 (p<0.05), whereas VLDL-C was significantly 
high (p<0.05) in all the groups when compared to controls. However, LDL-
C was significantly low in stage 5 only, as compared to control group 
(P<0.05). Though total cholesterol levels in stage 1 & 2 and LDL levels in 
stage 1-4 were higher than controls, the values attained were not statistically 
significant (P>0.05). HDL-C was lower in stage 5 CKD, but not significant. 
Data from National Health and Nutrition Examination Survey 
(NHANES) III and the Framingham Offspring Study, Data from multiple 
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observational studies kasiske85 & study in Singapore General Hospital 
conducted by CM Chan, Department of Renal Medicine reported in Ann 
Acad Med86, showed the below lipid abnormalities: 
   Total 
Cholesterol 
>240 mg/dl 
LDL Cholesterol 
>130 mg/dl 
HDL Cholesterol 
<35 mg/dl 
Triglycerides 
>200 mg/dl 
General population  20%  40% 15% 15% 
  With nephrotic 
syndrome 
90%  85% 50% 60% 
  Without nephrotic 
syndrome 
30%  10% 35% 40% 
  Hemodialysis  20%  30% 50% 45% 
  Peritoneal dialysis  25%  45% 20% 50% 
 
Prevalence of dyslipidemia, by guideline definitions, was 82%, 
predominantly manifested by elevated triglycerides (52%) and VLDL (52%) 
and decreased HDL (51%), with less frequent elevations of LDL (40%) and 
total cholesterol (24%), according to a study by Pennell P, et al., Division of 
Nephrology and Hypertension (R-126), Miller School of Medicine, 
University of Miami in University of Miami87. 
  In all of the above studies, CKD group was selected irrespective of the 
etiology. No exclusion for diabetes was made. In one study from Department 
of Hemodialysis and Renal Transplantation, Victor Babes University of 
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Medicine and Pharmacy, Timisoara88, an increase in TGs & decrease in 
HDL-C were noted in diabetic CKD as opposed to non diabetic CKD. LDL-C 
was increased in non-diabetic CKD. Diabetic patients without CKD had a 
higher TG & lower HDL-C when compared with non-diabetic CKD, which 
means diabetes possess higher dyslipidemic potency when compared with CKD 
per se.  
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RESULTS & ANALYSIS 
1) DISTRIBUTION OF STUDY GROUP ACCORDING TO AGE & SEX: 
 
 
 
 
 
 
 
 
Among the 80 cases and their age & sex matched controls, 72.5 % (58) 
are males and 27.5% (22) are females.  
 
AGE 
DISTRIBUTION 
(in yrs) 
MALE  FEMALE  TOTAL 
no  %  no  %  no  % 
30‐39  1  1.25  2  2.50  3  3.75 
40‐49  8  10.00  3  3.75  11  13.75 
50‐59  10  12.50  7  8.75  17  21.25 
60‐69  22  27.50 8 10.00 30 37.50 
70‐79  13  16.25  2  2.50  15  18.75 
≥80  4  5.00  0  0  4  5.00 
TOTAL  58  72.5 22 27.5 80 100 
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In the study group & their age - sex matched controls, 37.5% were in the 
60-69 yrs of age group. Next majority was in the 50-59 yrs age group (21.25%), 
followed by 70-79 yrs (18.75%), 40-49 yrs (13.75%), above 80 yrs (5%) and 
30-39 yrs (3.75%). 
 Among males, most of them were between 60-69 yrs (27.5%), followed 
by 70-79 yrs (16.25%), 50-59 yrs (12.5%), 40-49 yrs (10%), above 80 yrs (5%) 
and lastly 30-39 yrs (1.25%). 
 Among females, most of them were between 60-69 yrs (10%), followed 
by 50-59 yrs (8.75%), 40-49 yrs (3.75%). 30-39 yrs and 70-79 yrs formed 2.5% 
each. There were no females above 80 yrs in the study & control group.   
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2) COMPARISON OF BMI, UREA, CREATININE & CREATININE 
CLEARANCE AMONG STUDY AND CONTROL POPULATION: 
 
The mean BMI in the study group was 21.26 whereas that among the 
control was 22.44 and this difference was significant (p=0.0001; 95% CI 0.54 to 
1.83).  
The mean urea in the study group was 106.49 mg/dl & that in the control 
was 28.4 mg/dl, which is a significant difference (p=0.0001; 95% CI -87.33 to    
-68.85).  
The mean creatinine in the study group was 5.61 mg/dl & that in the 
control was 0.91 mg/dl and this difference is significant (p=0.0001; 95% CI       
-5.45 to -3.96).  
The mean creatinine clearance in the study group was 13.79 ml/min & 
that in the control was 68.07 ml/min (p=0.0001; 95% CI 51.81 to 56.75).  
 
 
CRITERIA  CONTROL  STUDY  MEAN 
DIFFERENCE 
SE 
DIFFERENCE 
P 
VALUE 
 
n  Mean  S.D  n  Mean S.D
BMI  80  22.44  1.74  80  21.26  2.35  1.18  0.32  .0001 Sig
UREA 
(mg/dl) 
80  28.40  5.04  80  106.49  41.23  78.09  4.64  .0001  Sig 
CREATININE 
(mg/dl) 
80  0.91  0.11  80  5.61  3.33  4.71  0.373  .0001  Sig 
CREATININE 
CLEARANCE 
(ml/min) 
80  68.07  8.44  80  13.79  7.31  54.28  1.24  .0001  Sig 
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3) DISTRIBUTION OF CREATININE CLEARANCE AMONG STUDY 
GROUP AND CONTROL POPULATION: 
CREATININE 
CLEARANCE 
(ml/min) 
STUDY  CONTROL 
NO  %  NO  % 
<10  30  37.5  0  0 
10‐19  35  43.75  0  0 
20‐29  12  15  0  0 
30‐39  3 3.75 0 0 
40‐49  0  0  0  0 
50‐59  0  0  3  3.75 
60‐69  0  0  54  67.5 
70‐79  0  0  11  13.75 
80‐89  0  0  10  12.5 
≥90  0  0  2  2.5 
TOTAL  80 100 80 100 
 
In the study group the creatinine clearance was below 39 ml/min and 
most of them had creatinine clearance below 19 ml/min. In the control 
population it was above 50 ml/min.  
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4) STAGING OF CKD AMONG STUDY GROUP - SEX WISE: 
 
 
 
 
 
 
 
 Most of the CKD cases were in stage 5 (63.75%). This distribution was 
maintained both in males & females. This was followed by stage 4 (32.5%) and 
then stage 3 (3.75%). 
 
STAGE 
MALE FEMALE TOTAL 
NO % NO % NO % 
3 3 3.75 0 0 3 3.75 
4 18 22.5 8 10 26 32.5 
5 37 46.25 14 17.5 51 63.75 
TOTAL 58 72.5 22 27.5 80 100 
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5) DISTRIBUTION OF LIPID ABNORMALITIES AMONG STUDY & 
CONTROL GROUP: 
 
 
In the study group, there was an increase in the total cholesterol, 
triglycerides & LDL and decrease in HDL when compared with the control 
population and the difference was significant by odds ratio (odds ratio > 1). 
LIPID 
ABNORMALITY 
STUDY  CONTROL   
ODDS RATIO 
 
95% CI 
NO  %  NO %
↑ TC  5  6.25  2  2.5 
 
2.60 
 
0.49 ‐ 13.81 
↑ TG  13  16.25  7  8.75 
 
2.02 
 
0.76 – 5.37 
↓ HDL  27  33.75  13  16.25 
 
2.62 
 
0.18 – 0.81 
↑ LDL  18  22.50  5  6.25  4.36 
 
1.53 – 12.40 
Dyslipidemia  36  45  18 22.5
 
2.82
 
‐ 
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Dyslipidemia (defined as presence of one or more lipid abnormalities) was 
present in 36 of the study group (45%) and 18 in the control group (22.5%) 
which was also significant by odds Ratio (2.82).  
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6) COMPARISON OF TOTAL CHOLESTEROL, TRIGLYCERIDES, 
HDL, TC/HDL, LDL-C & VLDL AMONG STUDY AND CONTROL 
POPULATION: 
 
 When compared with the control group, the study population had 
significantly increased total cholesterol (p=0.012), triglycerides (p=0.037), 
LDL-C (p=0.041) and TC/HDL ratio (p=0.002) and the decrease in the HDL-C 
was also significant (p=0.049) when compared with the control group. Whereas, 
there was an increase in VLDL-C in the study population when compared with 
the control group, but this increase was not significant (p=0.059).  
 
 
 
CRITERIA 
CONTROL  STUDY MEAN 
DIFFERENCE 
STD. ERROR 
DIFFERENCE 
P 
VALUE 
n  Mean  S.D  n  Mean  S.D 
TC  80  155.43  27.51  80  170.80  46.54  15.38  6.04  .012  Sig 
TG  80  136.80  30.00  80  154.15  67.58  17.35  8.26  .037  Sig 
HDL  80  38.50  3.579  80  37.15  4.93  1.35  0.68  .049  Sig 
TC/HDL  80  4.08  0.88  80  4.71  1.52  0.63  0.19  .002  Sig 
LDL‐C  80  89.68  26.46  80  101.60  44.41  11.93  5.78  .041  Sig 
VLDL  80  27.25  6.02  80  30.21  12.58  2.96  1.56  .059  Not 
sig 
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7) ANALYSIS OF LIPID ABNORMALITIES AMONG STUDY AND 
CONTROL POPULATION: 
 
On considering only the dyslipidemia population in both the study and 
control group, 36 in the study group (45%) had dyslipidemia and 18 in the 
control group (22.5%) had dyslipidemia.  
On analysing the above population alone, there was an increase in the 
prevalence of ÇTC & LDL-C but this increase was not statistically significant 
(p>0.05).But the decrease in HDL-C and increase in TGs in the study group 
were statistically significant when compared with the controls (p=0.006 & 
p=0.015, respectively). 
   
 
 
CRITERIA 
CONTROL  STUDY MEAN 
DIFFERENCE 
STD. ERROR 
DIFFERENCE 
P 
VALUE 
n  Mean  S.D  n  Mean  S.D 
Ç TC  2  242.00  .000  5  293.40  52.28  51.40  39.12  0.246  Not 
Sig 
Ç TG  7  214.71  11.87  13  272.85  73.46  58.13  28.30  0.015  Sig 
È HDL  13  33.31  0.95  27  31.70  1.88  1.60  0.55  0.006  Sig 
Ç LDL‐C  5  149.40  13.61  18  162.88  41.98  13.49  19.33  0.493  Not 
Sig 
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8) CKD STAGE WISE ANALYSIS OF LIPID ABNORMALITIES: 
CRITERIA STAGE 3 STAGE 4 STAGE 5 
Ç TC  0 % 0% 6.25% 
Ç TG 0% 7.5% 8.75% 
È HDL-C 0% 12.5% 21.25% 
Ç LDL-C 0% 6.25% 16.25% 
DYSLIPIDEMIA 0% 46.15% 47.06% 
  
In stage 3 CKD, no lipid abnormalities were noticed. In stage 4 & 5, 
dyslipidemia (defined as presence of one or more lipid abnormalities) was 
46.15% and 47.06% respectively.  
Total cholesterol was within the normal limits in stage 4 CKD group, 
whereas it was elevated in stage 5. The increase in TGs & LDL-C and decrease 
in HDL-C were higher in stage 5 when compared with stage 4.  
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9) SEX & CKD STAGE WISE DISTRIBUTION OF INCREASED 
TOTAL CHOLESTEROL: 
CKD-
STAGE 
MALE FEMALE TOTAL 
NO % NO % NO % 
3 0 0 0 0 0 0
4 0 0 0 0 0 0 
5 4 5 1 1.25 5 6.25
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10) SEX - WISE DISTRIBUTION OF TRIGLYCERIDES AMONG 
DIFFERRENT STAGES OF CKD: 
CKD-
STAGE 
MALE FEMALE TOTAL 
NO % NO % NO % 
3 0 0 0 0 0 0 
4 3 3.75 3 3.75 6 7.5 
5 5 6.25 2 2.5 7 8.75 
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11) SEX - WISE DISTRIBUTION OF HDL-C AMONG DIFFERRENT 
STAGES OF CKD: 
 
CKD-
STAGE 
MALE FEMALE TOTAL 
NO % NO % NO % 
3 0 0 0 0 0 0 
4 4 5 6 7.5 10 12.5 
5 13 16.25 4 5 17 21.25 
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12) SEX - WISE DISTRIBUTION OF LDL-C AMONG DIFFERRENT 
STAGES OF CKD: 
 
CKD-
STAGE 
MALE FEMALE TOTAL 
NO % NO % NO % 
3 0 0 0 0 0 0 
4 4 5 1 1.25 5 6.25 
5 8 10 5 6.25 13 16.25 
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13) COMPARISON OF TC, TG, HDL, TC/HDL, LDL-C & VLDL IN 
STUDY GROUP BETWEEN THOSE ON HEMODIALYSIS AND 
THOSE ON CONSERVATIVE MANAGEMENT: 
A comparison was made between the lipid status of the study group on 
conservative treatment and those on haemodialysis (HD). The analysis showed 
that the TG, LDL-C, VLDL & TC/HDL were higher in the conservatively 
managed group when compared with the HD group, but was not statistically 
significant (p>0.05). The total cholesterol level in the conservatively managed 
group was higher when compared with the HD group and this increase was 
statistically significant (p=0.018). The HDL-C was lower in the conservatively 
managed group when compared with the HD group, but was not statistically 
significant (p>0.05). 
CRITERIA 
 
HD  CONSERVATIVE 
MGMT 
MEAN 
DIFFERENCE 
STD. ERROR 
DIFFERENCE 
P 
VALUE 
 
n  Mean  S.D  n  Mean  S.D 
TC  19  150.21  39.72  61  177.21  46.93  27.00  11.92  0.018  Sig 
TG  19  149.58  85.86  61  155.57  61.58  5.99  17.86  0.738  Not 
Sig 
HDL  19  35.79  3.82  61  37.57  5.18  1.78  1.29  0.113  Not 
Sig 
LDL‐C  19  85.68  31.46  61  106.56  46.85  20.87  11.50  0.073  Not 
Sig 
VLDL  19  28.74  16.41  61  30.67  11.26  1.94  3.32  0.562  Not 
Sig 
TC/HDL  19  4.28  1.43  61  4.84  1.53  0.56  0.39  0.162  Not 
Sig 
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In the HD group (n=19), the prevalence of dyslipidemia was 31.58% (6 
patients had dyslipidemia), whereas in the conservatively managed group 
(n=61), the prevalence was 49.18% (30 patients had dyslipidemia).  
 
 
 
         LIPID 
ABNORMALITY 
CONSERVATIVE 
MGMT 
HD CONTROL 
 
n  NO  % 
 
n  NO  % 
 
n 
 
NO 
 
% 
↑ TC 
 
61  4  6.56 
 
19  1  5.26 
 
80 
 
2 
 
2.5 
↑ TG 
 
61  10  16.39
 
19 3 15.79
 
80
 
7 
 
8.75
↓ HDL 
 
61 
           
21  34.43 
 
19  6  31.58 
 
80 
 
13 
 
16.25 
↑ LDL 
 
61  17  27.87  19  1  5.26  80 
 
5 
 
6.25 
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DISCUSSION 
 
 CKD is a worldwide health problem and one of the growing, silent 
epidemic of non-communicable diseases. For a long time, dyslipidemia in CKD 
patients was an underestimated problem. Diabetes, nephrotic syndrome, thiazide 
diuretics and many secondary causes of dyslipidemia are well known to us and 
obviously CKD due to the above disorders (diabetes being the most common 
etiology) will have dyslipidemia. This study was hence undertaken to look, 
whether chronic kidney disease per se, possess a risk of dyslipidemia (without 
the above secondary causes of dyslipidemia) by excluding  obesity, diabetes, 
patients with nephrotic range of proteinuria, those on beta-blockers & OCPs, 
pregnant patients, patients with history of smoking and chronic alcohol intake. 
 80 such CKD patients were selected (who satisfied the above exclusion & 
inclusion criteria) and 80 age and sex matched, hospital based controls were 
also chosen and lipid profile was done on a fasting sample. The results obtained 
were statistically analysed.  
In this study of 80 patients, males predominated (72.5%) compared to 
females (27.5%). Majority of the males were in the age group of 60-79 yrs, 
whereas females were in the age group of 50-69 yrs.  
The mean BMI of the study group was significantly lower (21.26) than 
that of the control group (22.44) (p=0.0001).  This may be probably due to 
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malnourishment of the CKD patients. The mean blood urea level in the study 
group was 106.49 mg/dl & that in the control was 28.4 mg/dl, which is a 
significant difference (p=0.0001). The mean creatinine in the study group was 
5.61 mg/dl & that in the control was 0.91 mg/dl and this difference is also 
significant (p=0.0001).  
The mean creatinine clearance in the study group was 13.79 ml/min & 
that in the control was 68.07 ml/min, which again was significant. In the study 
group the creatinine clearance was below 39 ml/min and most of them had it less 
than 19 ml/min. In the control population it was above 50 ml/min and most of 
them had above 60 ml/min. 
The CKD patients were staged according to Kidney Disease Outcomes 
Quality Initiative (K/DOQI 2002) guidelines. Only 3.75% of them were in 
stage 3; 32.5% were in stage 4 & majority (63.75%) in stage 5. This distribution 
was maintained both in males & females. 
There was an increase in the prevalence of total cholesterol 
abnormality (6.25% in study group Vs 2.5% in controls), triglyceride 
abnormality (16.25% Vs 8.75%), LDL-C abnormality (22.5% Vs 6.25%) & 
HDL-C abnormality (33.75% Vs 16.25%) in the study group, when 
compared with the control group (odds ratio > 1). Dyslipidemia (defined as 
presence of one or more lipid abnormalities) was present in 36 of the study 
group (45%) and 18 in the control group (22.5%) (odds ratio=2.46).  
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             Comparing this data with the Data from National Health and 
Nutrition Examination Survey (NHANES) III and the Framingham 
Offspring Study , Data from multiple observational studies kasiske85 & 
study in Singapore General Hospital conducted by CM Chan, Department of 
Renal Medicine reported in Ann Acad Med86,  
  TC >240 
mg/dl 
LDL-C >130 
mg/dl 
HDL-C <35 
mg/dl 
TG >200 
mg/dl 
Control-NHANES III 20% 40% 15% 15% 
  Control-this study 2.5% 6.25% 16.25% 8.75% 
  CKD without nephrotic 
syndrome-conservative mgmt-
NHANES III 
30% 10% 35% 40% 
CKD without DM & Nephrotic 
proteinuria-conservative mgmt-
this study   
6.56% 27.87% 34.43% 16.39% 
HD-NHANES III 20% 30% 50% 45% 
HD-this study 5.26% 5.26% 31.58% 15.79% 
 
The prevalence of all the lipid abnormalities in this study were higher in 
the CKD population than the controls, the most significant being increased 
prevalence of total cholesterol & LDL-C. In the above NHANES III study, the 
prevalence of LDL-C abnormality in CKD population was lower than that in the 
control group and the main abnormality was increased TGs. 
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Comparing this study with the NHANES III study, the prevalence of total 
cholesterol and LDL-C abnormality is much lower in our population, even in 
the control group.  The prevalence of increased triglycerides is half that of 
western population in the normal control group, whereas the prevalence of 
HDL-C abnormality is slightly higher than that of the western population.                     
Comparing our study population on conservative treatment with that of the 
NHANES III (who has also excluded nephrotics in their study group but not 
DM or other secondary causes of dyslipidemia), the prevalence of increased 
LDL-C was twice higher than that of the western group. But the prevalence of 
total cholesterol & TG abnormality was much lesser. The prevalence of 
HDL-C abnormality is almost equal in both the groups. 
Comparing our study population on HD with that of the NHANES 
III group, the prevalence of all the lipid abnormalities were lower.  
When compared with the control group, the study population had 
significantly increased total cholesterol (p=0.012), triglycerides (p=0.037), 
LDL-C (p=0.041) and TC/HDL ratio (p=0.002) and the decrease in the HDL-C 
was also significant (p=0.049) when compared with the control group. Whereas 
there was an increase in VLDL-C in the study population when compared with 
the control group, but this increase was not significant (p=0.059).   
Comparing this study with a study conducted by B Shah, S Nair, et al., 
in Nephrology Section, PD Hinduja National Hospital's Research Centre, 
Mahim, Bombay83, following was observed:  
69 
 
 
Parameters 
(mean)       
(mg/dl) 
 
Control‐
Bombay 
study 
Control‐
this 
study 
CKD‐
conservativ
e mgmt‐
Bombay 
study
CKD‐
conservative 
mgmt‐this 
study
 
CKD‐HD‐
Bombay 
study 
CKD‐HD‐
this study 
TC 184.11 155.43 211.33 177.21* 163.37 150.21*
HDL-C 44.22 38.50 52.69 37.57* 49.37 35.79 
LDL-C 114.33 89.68 109.63 106.56* 89.84 85.68 
TG 127.78 136.80 222.78* 155.57* 121.16 149.58 
(* - p<0.05) 
The control population of the Bombay study had a higher TC, LDL-C 
and HDL-C & a lower TG when compared with our control population. The 
conservatively managed CKD group had TC and TG abnormality when 
compared with the control and the HD population.  Those on HD had a lower 
TC, LDL-c & TGs, but the HDL-C abnormality was noticed (p>0.05).  
In our study, conservatively managed group had an abnormality in 
the TC, HDL-C, LDL-C & TGs when compared with the control group 
(p<0.05). Comparing it with the conservatively managed group of the Bombay 
study, all the lipid parameters were lower. In the HD group, TC, LDL-C, TGs, 
VLDL-C & TC/HDL ratio were lower than the conservatively managed group, 
but p value was significant only for TC. HDL-C was low in the HD group 
than in the conservative management group, but not significant [p=0.17].   
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 In the HD group (n=19), the prevalence of dyslipidemia was 31.58% (6 
patients had dyslipidemia), whereas in the conservatively managed group 
(n=61), the prevalence was 49.18% (30 patients had dyslipidemia).  
   In addition in our study, TC/HDL ratio was higher in the study group 
(4.71) than the controls (4.01) which was significant (p=0.002). VLDL-C was 
also elevated in the study group but not significant (p=0.059). 
In stage 3 CKD, no lipid abnormalities were noticed. The prevalence of 
increase in TGs & LDL-C and decrease in HDL-C were higher in stage 5 when 
compared with stage 4. In stage 4 & 5, dyslipidemia (defined as presence of one 
or more lipid abnormalities) was 46.15% and 47.06% respectively.  
According to a study conducted by A. Madhusudhana Rao, et al., on lipid 
abnormalities, lipoprotein(a) and apoprotein pattern in non-dialyzed 
patients with CKD106, TGs were high in CKD stage 1-4 (p<0.05), whereas 
VLDL-C was significantly high (p<0.05) in all the groups when compared to 
controls. However, LDL-C was significantly low in stage 5 only as compared to 
control group (P<0.05). Though total cholesterol levels in stage 1 & 2 and LDL 
levels in stage 1-4 were higher than controls, the values attained were not 
statistically significant (P>0.05). HDL-C was lower in stage 5 CKD, but not 
significant. 
Prevalence of dyslipidemia, by guideline definitions, was 82%, 
predominantly manifested by elevated triglycerides (52%) and VLDL (52%) 
and decreased HDL (51%), with less frequent elevations of LDL (40%) and 
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total cholesterol (24%), according to a study by Pennell P, et al., Division of 
Nephrology and Hypertension (R-126), Miller School of Medicine, 
University of Miami in University of Miami87. 
  In all of the above studies, CKD group was selected irrespective of the 
etiology. No exclusion for diabetes was made. In one study from Department 
of Hemodialysis and Renal Transplantation, Victor Babes University of 
Medicine and Pharmacy, Timisoara88, the increase in TGs & decrease in 
HDL-C was noticed in diabetic CKD as opposed to non diabetic CKD. LDL-C 
was increased in non diabetic CKD. Diabetic patients without CKD had a 
higher TG & lower HDL-C when compared with non-diabetic CKD, which 
means diabetes possess higher dyslipidemic potency when compared with CKD 
per se.  
 Concluding, hypertriglyceridemia and elevated total cholesterol was the 
main abnormality in CKD patients on conservative management in other 
studies, this study shows significant elevation of total cholesterol, triglycerides, 
LDL-C and decreased HDL-C. In the hemodialysis group of other studies, total 
cholesterol, triglycerides, LDL-C and HDL-C were decreased, but not 
significant. Similar results were noted in this study too, with decrease in total 
cholesterol alone being significant. So chronic kidney disease per se, excluding 
the other causes of secondary dyslipidemia, possess lipid abnormalities.  
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                            CONCLUSION 
 This case - control study was aimed at finding out the prevalence and 
type of dyslipidemia in chronic kidney disease excluding the secondary causes 
of dyslipidemia like obesity, diabetes, nephrotic syndrome, beta-blocker intake, 
pregnant patients, etc., and comparing it with the age & sex matched controls. 
On analysis,  
a) There was an increase in the prevalence of dyslipidemia (elevated total 
cholesterol, LDL-C, triglycerides, VLDL-C & TC/HDL ratio and decreased 
HDL-C), as defined by the National Cholesterol Program (NCEP) Adult 
Treatment Panel (ATP) III guidelines.  
b) The major lipid abnormalities in the CKD population were elevated total 
cholesterol, triglycerides &LDL-C and decreased HDL-C.  
c) No lipid abnormality was noted in stage 3 CKD. In stage 4, there was an 
increase in triglycerides & LDL-C and decrease in HDL-C, while in stage 5 
there was an increase in total cholesterol, triglycerides & LDL-C and decrease 
in HDL-C.  
d) On comparing the conservatively managed group with the hemodialysis 
group, the prevalence of dyslipidemia was lower. Total cholesterol was 
significantly lower in hemodialysis population, but decrease in triglycerides, 
LDL-C, HDL-C and VLDL-C were not significant.  
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PROFORMA 
1. Name:    
2. Age:                     3. Sex: 
4. OP number:          Date: 
5. IP number:                                                   Date of admission:                            
6. Chief complaints: 
 
7. Diagnosis: 
8. Past history: a) hypertension: 
                            b) PD/HD: 
 
General examination:           
9. PR:                     /min.                                       10. BP:                     mmHg.                          
 
11. Height:                 m.                                       12. Weight:            Kg. 
 
13. BMI:                                                                 14. Pallor: 
 
Systemic examination:  
15. CVS: 
      
16. RS: 
 
17. Abdomen: 
      
18. CNS: 
84 
 
      
19. Eye ‐ fundus:  
    
Investigations: 
20. Hemoglobin:                 g/dl 
21. Blood sugar :               mg/dl                             22. Blood urea:                mg/dl 
23. S.creatinine:               mg/dl 
 
24. Creatinine clearance (calculated):                  ml/min 
 
25. Electrolytes (mEq/L): Na:                  K:                  Cl:                  HCO3: 
 
26. USG Abdomen: 
 
      
27. Fasting Lipid Profile:  
            a) Total cholesterol:               mg/dl              b) TG:                      mg/dl                   
            c) HDL:                                     mg/dl              d) LDL:                     mg/dl  
            e) VLDL:                                   mg/dl              e) TC/HDL ratio: 
 
28. ECG: 
 
29. Urine analysis:               
 
 
                             
        
CONTROL                            
S.NO                NAME 
   
AGE 
  
SEX
HEIGHT  
(cm)
WEIGHT   
(Kg)   BMI
    FBS 
(mg/dl)
     PP 
(mg/dl) 
 UREA 
(mg/dl) 
CREATININE     
(mg/dl)
CREATININE 
CLEARANCE 
(ml/min)
TO
CHOL
(m
1  MURUGESAN  60  M  150  55  24.44  81  115  23  0.9  67.90 
2  MURUGAN  32  M  159  60  23.73  88  124  29  1.0  90.00 
3  VELLAYAN  40  M  158  62  24.83  95  132  23  1.0  86.11 
4  YASODHAI  52  F  148  53  24.20  91  128  21  0.9  61.18 
5  CHANDRAN  55  M  160  54  21.09  96  137  27  1.0  63.75 
6  DEIVASIGAMANI  57  M  157  56  22.71  85  129  22  0.9  71.73 
7  VENU  60  M  156  60  24.69  97  136  32  1.1  60.61 
8  ELLAPPAN  70  M  158  62  24.83  92  118  32  1.0  60.28 
9  RADHAKRISHNAN  70  M  165  64  23.52  97  121  26  1.0  62.22 
10  KANNIYAPPAN  65  M  158  61  24.43  94  126  25  1.0  63.54 
11  DHAYALAN  60  M  164  59  22.01  86  120  24  1.0  65.56 
12  JOTHI  60  F  165  60  22.05  63  113  36  0.9  62.96 
13  LOGU  50  F  168  58  20.54  90  121  24  0.9  68.47 
14  SEKHAR  80  M  165  57  20.95  78  112  35  0.8  59.38 
15  KANNAN  61  M  155  55  22.91  85  124  22  1.0  60.35 
16  RAJASEKHAR  70  M  163  60  22.64  92  135  31  0.8  72.92 
17  RAJAM  60  F  158  58  23.29  79  125  25  0.8  68.47 
18  PAPPAMMAL  65  F  158  55  22.08  87  110  28  0.8  60.87 
19  PAKKIRI  60  M  157  47  19.10  76  123  34  0.8  65.28 
20  RAJARAMAN  70  M  160  54  21.09  80  130  30  0.8  65.63 
21  CHINNAMMAL  35  F  158  60  24.09  97  133  26  1.0  74.38 
22  MEENAKSHI  45  F  162  59  22.51  94  122  33  0.9  73.52 
23  ANANDHAN  75  M  158  57  22.89  90  135  39  0.8  64.32 
24  ARUMUGAM  61  M  154  46  19.40  96  115  21  0.8  63.09 
25  ARUL  65  M  162  64  22.42  82  134  27  1.0  66.67 
26  MAHESH  70  M  163  62  23.39  75  108  24  1.0  60.28 
27  PATAMMAL  50  F  153  46  19.65  90  120  36  0.8  61.09 
28  ARJUN  80  M  165  61  22.42  84  105  21  0.8  63.54 
29  RAGUPATHI  53  M  158  62  24.89  96  111  38  1.2  62.43 
30  MINI  70  F  157  59  23.98  77  128  27  0.8  60.95 
31  MURUGAMMAL  50  F  153  48  20.50  76  132  22  0.8  63.75 
32  ARULANANDHAM  70  M  163  49  18.49  86  118  35  0.7  68.06 
33  ETTIYAPPAN  50  M  165  57  20.95  97  109  31  1.1  64.77 
34  MANI  80  M  160  58  22.65  92  124  24  0.8  60.42 
35  THILAGAM  60  F  158  57  22.89  84  134  34  0.8  67.29 
36  BABU  82  M  157  60  24.39  81  138  28  0.8  60.42 
37  ANBUMURUGARAJ  65  M  160  60  23.43  88  119  21  1.0  62.50 
38  JEGADEESAN  54  M  154  53  22.34  95  126  26  1.0  63.31 
39  ELAVARASI  70  F  155  58  24.16  91  133  31  0.7  68.47 
40  VALLI  65  F  152  51  22.07  80  116  35  0.8  56.44 
41  VINAYAGAM  60  M  157  54  21.90  76  109  22  0.8  75.00 
42  KANNAN  45  M  162  51  19.46  94  120  31  1.1  61.17 
43  SIVAKUMARAN  55  M  158  53  21.28  80  134  26  0.9  69.52 
44  JAMAL  70  M  165  58  22.65  90  117  23  0.9  62.65 
45  RAJESHWARI  60  F  157  60  24.39  76  126  34  0.9  62.96 
46  CHITHAMBARAM  60  M  165  57  20.95  84  106  38  1.0  63.33 
47  MOHAN  60  M  159  62  24.60  79  138  24  1.0  68.89 
48  GOWRI  68  F  162  57  21.75  91  117  27  0.8  60.56 
49  CHANDRAN  60  M  168  70  24.82  82  133  35  0.9  86.42 
50  AMMU  50  F  160  60  23.43  82  129  30  0.9  70.83 
51  MURUGAN  40  M  159  47  18.65  91  110  23  0.8  81.60 
52  GUNASEKARAN  55  M  168  70  24.82  78  121  28  1.0  82.64 
53  MUNUSAMY  48  M  164  62  23.13  93  135  31  0.9  88.02 
54  VASUDEVAN  55  M  160  56  21.87  83  106  24  1.1  60.10 
55  MADHAVAN  50  M  165  67  24.63  92  128  38  1.0  83.75 
56  HARI  48  M  156  58  23.86  85  119  23  1.0  74.11 
57  MANOHARAN  60  M  163  66  24.90  78  132  31  0.9  81.48 
58  SARANGAPANI  63  M  158  53  21.28  74  104  30  0.9  62.98 
59  PALANI  69  M  160  63  24.60  86  129  26  1.0  62.13 
60  PADMA  42  F  159  52  20.63  97  134  32  0.8  75.20 
61  IKBAL  76  M  170  70  24.42  90  103  23  1.0  62.22 
62  SELVAM  48  M  172  63  21.28  84  121  30  1.0  80.50 
63  DILIP  74  M  161  53  20.46  80  112  34  0.8  60.73 
64  ELAMARAN  62  M  172  63  21.28  74  117  37  1.0  68.25 
65  HEMACHANDRAN  61  M  158  52  20.88  91  138  24  0.9  63.40 
66  SUDHAKARAN  73  M  172  63  21.28  87  127  29  0.9  65.14 
67  CHINNAPPAN  77  M 164 58 21.64 78 104  22  0.8 63.44
68  MURALINADHAN  60  M  166  52  18.90  86  131  30  0.9  64.20 
69  KRISHNAN  57  M  165  58  21.32  69  115  32  0.8  83.58 
70  PALANI  49  M  160  57  22.26  87  118  29  0.8  90.05 
71  FATHIMA BEGAM  67  F  151  53  23.24  84  127  22  0.8  57.09 
72  KUTTIAPPAN  60  M  163  65  24.52  95  106  28  1.0  72.22 
73  ANDAL  30  F 161 56 21.62 73 123  34  1.1 66.11
74  AISHABEE  43  F  150  46  20.44  86  129  23  0.8  65.85 
75  VENKATASAMY  68  M  166  54  19.63  82  134  31  0.7  77.14 
76  SARASWATHY  59  F  159  62  24.60  70  122  28  0.9  65.88 
77  PRABAVATHY  55  F  162  64  24.42  92  116  36  1.0  64.22 
78  KANNIAPPAN  47  M  163  59  22.26  85  132  26  0.9  84.68 
79  SIVARAMAN  70  M  63  62  23.39  79  118  23  1.0  60.28 
80  PARTHIBAN  62  M  160  55  21.48  80  120  27  0.8  74.48 
 
STUDY GROUP 
S.NO               NAME    AGE    SEX 
HEIGHT       
(cm) 
 WEIGHT     
(Kg)     BMI 
FBS 
(mg/dl) 
      PP 
(mg/dl) 
 UREA 
(mg/dl) 
CREATININE       
(mg/dl) 
CREATININE 
CLEARANCE       
(ml/min) 
1  DHAKSHANAMOORTHY  60  M  155  45  18.73  92  137  96  4.2  11.90 
2  BALASUBRAMANI  32  M  152  40  17.31  88  112  148  5.8  10.34 
3  CHINNAPPAN  40  M  160  60  23.43  86  138  126  8.8  09.46 
4  NAGAMMAL  52  F  155  48  19.97  96  135  87  2.9  17.19 
5  ERUSAN  55  M  160  49  19.54  87  102  121  5.4  10.71 
6  VADIVEL  57  M  150  41  18.22  77  112  120  2.7  17.50 
7  THAMBIRAN  60  M  148  38  17.34  98  132  94  3.1  13.62 
8  MUTHU  70  M  157  42  19.43  85  124  172  3.5  11.66 
9  KANNIYAPPAN  70  M  147  36  16.65  100  126  135  2.6  13.46 
10  RAMAKRISHNAN  65  M  154  53  22.34  73  139  64  2.1  26.28 
11  ARUMUGAM  60 M 160 62 24.21 85 127  67  2.1 32.80
12  BALAMMAL  60  F  157  43  17.44  98  120  72  3.0  13.53 
13  VANATHAI  50  F  152  51  22.07  86  129  128  4.1  13.21 
14  KANNAPPAN  80  M  153  48  20.50  83  113  54  2.2  18.18 
15  BABU  61  M  157  54  21.90  93  128  155  7.2  08.22 
16  YEHAPPAN  70  M  162  59  22.51  84  107  65  3.9  14.70 
17  NAGAMMAL  60  F  156  58  23.86  98  124  108  3.1  18.88 
18  MUNIYAMMAL  65  F  157  60  24.39  88  132  93  4.2  12.64 
19  RAMDOSS  60  M  158  53  21.28  92  119  86  2.7  21.81 
20  VAJRAVELU  70  M  158  57  22.89  99  137  64  3.2  17.31 
21  CHELLAMMAL  35  F  156  56  23.04  68  103  174  6.4  10.84 
22  SAKUNTHALA  45  F  156  41  16.87  98  138  98  3.2  14.36 
23  KRISHNASAMY  75  M  165  57  20.95  95  129  60  2.4  21.44 
24  ARUMUGAM  61  M  160  58  22.65  87  127  80  3.9  16.31 
25  NARAYANASAMY  65  M  165  61  22.42  84  116  92  3.6  17.65 
26  MUNUSAMY  70  M  159  62  24.60  73  132  162  7.4  08.14 
27  LAKSHMI  50  F  162  57  21.75  85  111  97  4.5  13.45 
28  RAJ  80  M  163  49  18.49  94  123  65  2.5  16.33 
29  SELVARAJ  53  M  163  62  19.62  84  135  136  8.5  08.81 
30  VALLIAMMAL  70  F  160  55  21.48  82  113  115  2.8  16.23 
31  KANNIAMMAL  50  F  163  60  22.64  97  129  67  2.3  27.71 
32  DHARMALINGAM  70 M 168 70 24.82 74 118  88  4.6 14.79
33  MAHENDRAN  50  M  168  62  18.43  93  124  191  7.9  09.81 
34  RAMAN  80  M  160  56  21.87  92  129  67  2.8  16.66 
35  CHINNAKOLANTHAI  60  F  152  56  24.24  87  112  64  2.5  21.15 
36  RAGHAVAN  82  M  165  67  24.63  72  103  102  4.3  12.55 
37  SUBRAMANI  65  M  163  66  24.90  92  129  185  9.9  06.94 
38  SAMRAJ  54  M  168  64  22.69  98  134  116  7.5  10.19 
39  NEELAMMAL  70  F  151  53  23.24  93  115  116  5.2  08.42 
40  ANJALATCHI  65  F  155  55  22.91  87  132  60  2.8  17.39 
41  DURAISAMY  60  M  163  62  23.39  83  121  68  3.3  20.87 
42  MUNUSAMY  45  M  160  60  23.43  99  137  69  2.8  28.27 
43  MANI  55  M  158  53  21.28  85  139  59  3.6  17.38 
44  EGAMBARAM  70  M  160  63  24.60  78  128  103  9.7  06.31 
45  ANJALAI  60  F  153  46  19.65  74  115  64  3.0  14.48 
46  PERIYASAMY  60  M  160  63  24.60  80  132  60  2.2  31.81 
47  VELLAYAN  60  M  170  70  24.42  94  131  112  7.8  09.97 
48  MUNIYAMMAL  68  F  160  55  21.48  91  128  104  2.7  17.31 
49  SUNDARAMURTHY  60  M  161  53  20.46  97  126  97  5.9  09.98 
50  MURUGAMMAL  50 F 158 52 20.88 70 132  181  12.0 04.60
51  SHANKAR  40  M  172  63  21.28  93  134  32  2.6  30.28 
52  ARUMUGAM  55  M  176  58  18.77  87  139  65  4.6  14.88 
53  MUNUSAMY  48  M  164  58  21.64  80  137  138  7.7  09.62 
54  MARUTHAN  55  M  158  52  20.88  91  134  87  2.1  29.23 
55  PANCHACHARAM  50  M  164  61  22.76  92  126  123  5.4  14.12 
56  MUNUSAMY  48  M  166  52  18.90  75  118  67  2.6  25.55 
57  KANNIYAPPAN  60  M  157  47  19.10  84  128  74  2.6  20.08 
58  MUNUSAMY  63  M  163  65  24.52  89  132  107  6.3  11.03 
59  LAKSHMANA RAJA  69  M  158  50  20.08  98  138  88  9.0  05.47 
60  RANI  42  F  150  46  20.44  68  112  163  9.6  05.54 
61  RAJAMANI  76  M  157  44.5  18.08  89  109  69  6.4  06.18 
62  PONROSE  48  M  162  64  24.42  79  115  192  12.7  06.43 
63  SANTHANAM  74  M  157  50  20.32  88  117  104  7.3  06.27 
64  SAMBUNATH  62  M  163  62  23.39  93  128  152  8.7  07.72 
65  DHASARATHAN  61  M  160  48  18.75  88  132  134  15.9  03.31 
66  ARUMUGAPILLAI  73  M  162  47  17.93  83  120  72  9.4  04.65 
67  CHEZHIYAN  77  M  161  48  18.75  87  139  177  8.5  04.94 
68  PAUL THANGARAJ  60  M  160  55  21.48  93  134  94  6.3  09.70 
69  FRANKLIN  57  M  158  57  22.89  82  137  128  12.8  05.13 
70  VENKATACHALAM  49  M  160  55  21.48  67  119  212  14.1  04.93 
71  KAVANNA  67 F 160 44 17.18 65 101  87  8.0 04.73
72  SOLOMON  60  M  161  49  19.14  72  126  113  9.2  05.91 
73  INDIRA DEVI  30  F  158  50  20.08  86  120  106  10.5  06.18 
74  DHAMAYANDHI  43  F  166  54  19.63  88  123  121  10.0  06.18 
75  ARUMUGAM  68  M  156  48  19.75  85  117  130  6.7  07.16 
76  RATHINAMARY  59  F  162  61  23.82  89  109  158  12.7  04.59 
77  POONGAVANAM  55  F  160  62  24.21  89  136  53  2.5  24.88 
78  KUPPAN  47  M  157  40  16.26  85  120  92  4.3  12.01 
79  SELVARAJ  70  M  165  60  22.05  94  114  205  2.3  25.36 
80  THIRUVENGADAM  62  M  158  56  22.48  78  110  69  3.4  17.84 
 
